Novartis Stock Price, News & Analysis (NYSE:NVS)

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Novartis declared an annual dividend on Thursday, January 31st. Shareholders of record on Tuesday, March 5th will be given a dividend of $2.8646 per share on Wednesday, March 13th. This represents a yield of 3.27%. The ex-dividend date is Monday, March 4th. This is a boost from Novartis's previous annual dividend of $2.33. View Novartis' Dividend History.

Novartis AG (NYSE:NVS) released its quarterly earnings data on Thursday, October, 18th. The company reported $1.32 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.31 by $0.01. The firm had revenue of $12.78 billion for the quarter, compared to the consensus estimate of $12.88 billion. Novartis had a return on equity of 18.55% and a net margin of 23.27%. Novartis's revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.29 EPS. View Novartis' Earnings History.

Novartis is scheduled to release their next quarterly earnings announcement on Tuesday, October 22nd 2019. View Earnings Estimates for Novartis.

Novartis will be holding an earnings conference call on Tuesday, October 22nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

12 analysts have issued twelve-month price objectives for Novartis' shares. Their forecasts range from $79.16 to $105.00. On average, they anticipate Novartis' share price to reach $91.94 in the next twelve months. This suggests a possible upside of 5.8% from the stock's current price. View Analyst Price Targets for Novartis.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 4 sell ratings, 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.

News headlines about NVS stock have been trending somewhat negative on Saturday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novartis earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Novartis.

Novartis saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 3,110,000 shares, a decline of 13.1% from the August 30th total of 3,580,000 shares. Based on an average trading volume of 2,000,000 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.1% of the company's shares are sold short. View Novartis' Current Options Chain.

Some companies that are related to Novartis include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Cisco Systems (CSCO), NVIDIA (NVDA), AT&T (T), Gilead Sciences (GILD) and Merck & Co., Inc. (MRK).

Novartis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (0.11%), Bristol John W & Co. Inc. NY (0.03%), Envestnet Asset Management Inc. (0.03%), Douglas Lane & Associates LLC (0.01%), Country Trust Bank (0.01%) and Gofen & Glossberg LLC IL (0.01%).

NVS stock was sold by a variety of institutional investors in the last quarter, including Thomasville National Bank, Manning & Napier Group LLC, Scout Investments Inc., Crossmark Global Holdings Inc., Country Trust Bank, Country Club Trust Company n.a., Endurance Wealth Management Inc. and Park National Corp OH.

NVS stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Ferguson Wellman Capital Management Inc., CIBC Private Wealth Group LLC, Confluence Investment Management LLC, Bristol John W & Co. Inc. NY, Whittier Trust Co., Avitas Wealth Management LLC and Fox Run Management L.L.C..

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVS stock can currently be purchased for approximately $86.88.

Novartis has a market capitalization of $199.11 billion and generates $51.90 billion in revenue each year. The company earns $12.61 billion in net income (profit) each year or $5.09 on an earnings per share basis. Novartis employs 125,161 workers across the globe.View Additional Information About Novartis.

The official website for Novartis is http://www.novartis.com/.

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 011-41-61-324-1111 or via email at [email protected]